<p><strong>Pediatric Use</strong>: Safety and effectiveness of Ribavirin in combination with Peginterferon has not been established in pediatric patients below the age of 3 years.<br />
<br />
<strong>Geriatric Use</strong>: The risk of toxic reactions to this drug may be greater in patients with impaired renal function. The dose of Ribavirin&nbsp;should be reduced in patients with creatinine clearance less than or equal to 50 ml/min; and the dose of Interferon should be reduced in patients with creatinine clearance less than 30 ml/min.</p>